NCT02390466View on ClinicalTrials.gov

Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
HIV
Interventions
BIOLOGICAL

VAC-3S

Administered via intra-muscular injection in the arm

Trial Locations (2)

75013

Hôpital Pitié Salpêtrière, Paris

75014

Hôpital Cochin Saint Vincent de Paul, Paris

Sponsors

Lead Sponsor

InnaVirVax
All Listed Sponsors
lead

InnaVirVax

INDUSTRY

NCT02390466 - Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1 | Biotech Hunter | Biotech Hunter